Your browser is no longer supported. Please, upgrade your browser.
Cara Therapeutics, Inc.
Index- P/E26.81 EPS (ttm)0.44 Insider Own2.80% Shs Outstand50.12M Perf Week-1.51%
Market Cap629.22M Forward P/E- EPS next Y-1.39 Insider Trans-3.13% Shs Float44.69M Perf Month-4.07%
Income23.90M PEG- EPS next Q-0.52 Inst Own58.00% Short Float4.18% Perf Quarter-7.32%
Sales134.30M P/S4.69 EPS this Y107.00% Inst Trans-0.45% Short Ratio2.76 Perf Half Y-2.49%
Book/sh4.13 P/B2.85 EPS next Y12.40% ROA9.90% Target Price26.25 Perf Year-40.10%
Cash/sh2.70 P/C4.36 EPS next 5Y- ROE10.70% 52W Range10.83 - 29.65 Perf YTD-3.37%
Dividend- P/FCF- EPS past 5Y16.80% ROI2.40% 52W High-60.47% Beta1.00
Dividend %- Quick Ratio11.00 Sales past 5Y104.20% Gross Margin- 52W Low8.22% ATR0.56
Employees84 Current Ratio11.00 Sales Q/Q118.30% Oper. Margin16.90% RSI (14)42.63 Volatility5.65% 4.55%
OptionableYes Debt/Eq0.00 EPS Q/Q94.30% Profit Margin17.80% Rel Volume0.26 Prev Close11.77
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout0.00% Avg Volume677.89K Price11.72
Recom1.90 SMA20-2.69% SMA50-8.06% SMA200-19.66% Volume125,566 Change-0.42%
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Jan-10-22 08:00AM  
Jan-03-22 04:01PM  
Dec-20-21 07:00AM  
Dec-14-21 05:10AM  
Nov-18-21 08:30AM  
Nov-17-21 12:01PM  
Nov-09-21 04:30PM  
Nov-08-21 08:30PM  
Nov-03-21 08:00AM  
Nov-01-21 04:15PM  
Oct-26-21 10:18AM  
Oct-15-21 06:59AM  
Oct-04-21 07:00AM  
Sep-29-21 07:00AM  
Sep-24-21 07:00AM  
Sep-20-21 04:26PM  
Sep-04-21 08:55AM  
Aug-27-21 05:33PM  
Aug-24-21 04:08PM  
Aug-23-21 07:06PM  
Aug-15-21 08:07AM  
Aug-11-21 10:22AM  
Aug-09-21 09:00PM  
Aug-04-21 07:04PM  
Aug-02-21 04:01PM  
Jul-29-21 03:53PM  
Jul-12-21 10:26AM  
Jun-11-21 07:30AM  
Jun-10-21 02:02AM  
May-29-21 06:41AM  
May-25-21 07:00AM  
May-23-21 06:30AM  
May-10-21 08:30PM  
May-06-21 04:01PM  
May-03-21 04:01PM  
Apr-29-21 11:33AM  
Apr-07-21 04:01PM  
Apr-06-21 10:59AM  
Apr-05-21 06:55PM  
Mar-31-21 07:00AM  
Mar-30-21 12:01PM  
Mar-29-21 04:58PM  
Mar-08-21 09:28AM  
Feb-26-21 08:01AM  
Feb-25-21 04:01PM  
Feb-24-21 10:13AM  
Feb-18-21 04:01PM  
Feb-10-21 12:38AM  
Feb-07-21 02:13PM  
Feb-03-21 03:21AM  
Jan-11-21 07:00AM  
Jan-08-21 08:56AM  
Jan-06-21 07:00AM  
Dec-28-20 07:00AM  
Dec-24-20 07:30AM  
Dec-22-20 04:05PM  
Dec-18-20 12:19AM  
Dec-02-20 07:00AM  
Nov-17-20 01:16PM  
Nov-12-20 05:42AM  
Nov-11-20 07:00AM  
Nov-09-20 09:00PM  
Nov-02-20 04:01PM  
Oct-27-20 04:05PM  
Oct-22-20 12:00PM  
Oct-21-20 04:01PM  
Oct-20-20 03:30PM  
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ives Jeffrey L.DirectorNov 12Sale16.048,180131,2077,200Nov 16 06:15 PM
Goncalves JoanaChief Medical OfficerNov 01Sale17.151,00017,15045,900Nov 03 04:55 PM
Goncalves JoanaChief Medical OfficerOct 27Sale15.001,00015,00046,900Oct 28 06:34 PM
CHALMERS DEREK TPresident & CEOSep 07Sale15.4720,000309,400991,405Sep 09 04:48 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Aug 30Sale14.201,75924,97870,917Sep 01 06:09 PM
Reilly Thomas CharlesChief Financial OfficerAug 30Sale14.201,98228,1443,352Sep 01 06:08 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DAug 30Sale14.203,84754,627141,072Sep 01 06:07 PM
Goncalves JoanaChief Medical OfficerAug 30Sale14.202,11029,96247,900Sep 01 06:06 PM
CHALMERS DEREK TPresident & CEOAug 30Sale14.208,440119,8481,011,405Sep 01 06:04 PM
VOGELBAUM MARTINDirectorJun 07Sale13.058,640112,75220,160Jun 07 07:35 PM
Posner ChristopherDirectorJun 07Sale13.042,30430,04416,096Jun 07 07:33 PM
Ives Jeffrey L.DirectorJun 07Sale13.052,52032,88615,380Jun 07 07:25 PM
Goncalves JoanaChief Medical OfficerApr 21Sale27.633,00082,89043,610Apr 23 05:05 PM
Goncalves JoanaChief Medical OfficerMar 22Sale19.653,00058,95030,610Mar 24 05:55 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 05Sale17.983,35860,377119,319Mar 08 05:48 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Mar 05Sale17.983,09055,55851,342Mar 08 05:47 PM
Goncalves JoanaChief Medical OfficerMar 05Sale17.983,09355,61233,610Mar 08 05:45 PM
CHALMERS DEREK TPresident & CEOMar 05Sale17.983,10355,792950,511Mar 08 05:44 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Feb 25Sale19.334,00477,39744,432Feb 25 09:06 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DFeb 25Sale19.335,00396,708112,677Feb 25 09:05 PM
Goncalves JoanaChief Medical OfficerFeb 25Sale19.333,37265,18126,703Feb 25 09:04 PM
CHALMERS DEREK TPresident & CEOFeb 25Sale19.3311,729226,722943,614Feb 25 09:02 PM
Goncalves JoanaChief Medical OfficerFeb 22Sale19.732,00039,46026,075Feb 24 05:02 PM